{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019267","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.074440+00:00","generated_at":"2026-06-25T22:08:05.520383+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arrowhead Q2 FY2022 net income $44.4M on revenue $151.8M vs prior year loss","bullets":["Revenue $151.8M for Q2 ended Mar 31, 2022, up from $32.8M YoY; net income $44.4M ($0.41 diluted EPS) vs net loss $26.8M ($0.26 loss) year ago.","Initiated PALISADE Phase 3 study of ARO-APOC3 in familial chylomicronemia syndrome; completed enrollment of 204 patients in Phase 2b ARCHES-2 for ARO-ANG3.","Formed Visirna Therapeutics joint venture with Vivo Capital to expand into Greater China.","Broke ground on new manufacturing facility; awarded up to $18.5M in tax incentives from Wisconsin and Verona.","Total cash and investments of $603.5M as of March 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019267","json":"https://secwatch.observer/filing/0001564590-22-019267.json","markdown":"https://secwatch.observer/filing/0001564590-22-019267.md","text":"https://secwatch.observer/filing/0001564590-22-019267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/0001564590-22-019267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000156459022019267/arwr-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:08:05.520383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}